000 05558nam a22005895i 4500
001 978-3-031-59815-9
003 DE-He213
005 20251030112845.0
007 cr nn 008mamaa
008 240809s2024 sz | s |||| 0|eng d
020 _a9783031598159
_9978-3-031-59815-9
024 7 _a10.1007/978-3-031-59815-9
_2doi
050 4 _aQR180-189.5
072 7 _aMJCM
_2bicssc
072 7 _aMED044000
_2bisacsh
072 7 _aMJCM
_2thema
245 1 0 _aCytokine Storm Syndrome
_h[electronic resource] /
_cedited by Randy Q. Cron, Edward M. Behrens.
250 _a2nd ed. 2024.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2024.
300 _aXVI, 628 p. 43 illus., 35 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aAdvances in Experimental Medicine and Biology,
_x2214-8019 ;
_v1448
505 0 _a1. Cytokines in cytokine storm syndromes -- 2. History of HLH -- 3. The history of macrophage activation syndrome in autoimmune diseases -- 4. Clinical features of cytokine storm syndromes -- 5. Laboratory features and pathology of cytokine storm syndromes -- 6. Criteria for cytokine storm syndromes -- 7. Familial HLH genetics -- 8. Secondary HLH genetics -- 9. Genetics of macrophage activation syndrome in systemic juvenile idiopathic arthritis -- 10. CD8+ T cell biology in cytokine storm syndromes -- 11. Immunology of cytokine storm syndromes: Natural killer cells -- 12. Myeloid cells in the immunopathogenesis of cytokine storm syndrome -- 13. Cytokine storm -- 14. Primary immunodeficiencies -- 15. Infectious triggers of cytokine storm syndromes: Herpes virus family (non-EBV) -- 16. CSS associated with Epstein Barr Virus -- 17. Hemorrhagic Fever and other viruses -- 18. Cytokine storm syndrome as a manifestation of primary HIV infection -- 19. Bacteria-associated cytokine storm syndrome -- 20. Zoonoticbacterial infections triggering cytokine storm syndrome -- 21. Parasitic and fungal triggers -- 22. COVID-19 pneumonia and cytokine storm syndrome -- 23. Cytokine storm associated with Systemic Juvenile Idiopathic Arthritis -- 24. Systemic lupus erythematosus -- 25. Kawasaki disease -- 26. The intersections of autoinflammation and cytokine storm -- 27. Other rheumatic triggers -- 28. Multisystem Inflammatory Syndrome in children -- 29. Hemophagocytic lymphohistiocytosis in the context of hematological malignancies and solid tumors -- 30. Cytokine storm and sepsis-induced Multiple Organ Dysfunction Syndrome -- 31. The cytokine storm of Multicentric Castleman Disease -- 32. Cytokine storm syndromes associated with pregnancy and therapeutics -- 33. fHLH models -- 34. sHLH models -- 35. Etoposide therapy of CSS -- 36. IL-1 family blockade -- 37. IL-6 blockade -- 38. IFNy blockade -- 39. JAK inhibitors -- 40. Other immunomodulatory HLH treatments -- 41. Salvage therapy for HLH.
520 _aCytokine Storm Syndromes, including HLH and MAS, are frequently fatal disorders, particularly if not recognized early and treated during presentation. The genetics of Cytokine Storm Syndromes are being defined with many of the risk alleles giving rise to mutations in the perforin-mediated cytolytic pathway used by CD8 cytotoxic T cells and natural killer cells. These are being studied using murine models. Up to 10% of the general population may carry risk alleles for developing Cytokine Storm Syndromes, and Cytokine Storm Syndromes are being increasingly recognized around the world in pediatric and adult hospitals. A variety of infectious, rheumatic, and oncologic triggers are commonly associated with Cytokine Storm Syndromes, but understanding this disorder is critical for all researchers and physicians to ensure timely and appropriate therapy. This second edition addresses all aspects of the disorder, from genetics, pathophysiology, and ongoing research, to clinical presentations, risk factors and treatment. New-to-this-edition features include dedicated chapters on severe COVID-19 CSS, and post-COVID CSS of multi-system inflammatory syndrome in children (MIS-C). In addition, novel topics including CSS associated with Castleman disease, pregnancy, therapeutics, transplantation, and cardiac bypass, as well as treatment with JAK inhibitors are addressed. .
650 0 _aImmunology.
_969214
650 0 _aMolecular genetics.
650 0 _aDiseases.
_968840
650 0 _aCytokines.
_982114
650 1 4 _aImmunology.
_969214
650 2 4 _aMolecular Genetics.
650 2 4 _aDiseases.
_968840
650 2 4 _aCytokines and Growth Factors.
_982115
700 1 _aCron, Randy Q.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_982116
700 1 _aBehrens, Edward M.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_982117
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031598142
776 0 8 _iPrinted edition:
_z9783031598166
776 0 8 _iPrinted edition:
_z9783031598173
830 0 _aAdvances in Experimental Medicine and Biology,
_x2214-8019 ;
_v1448
_967831
856 4 0 _uhttps://doi.org/10.1007/978-3-031-59815-9
912 _aZDB-2-SBL
912 _aZDB-2-SXB
999 _c62343
_d62343